Pitavastatin: The newest HMG-CoA reductase inhibitor

Reviews in Cardiovascular Medicine

Volumn 11, Issue 1, 2010, Pages 26-32

  Watson, Karol E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary heart disease; HDL cholesterol; LDL cholesterol; Statins; Triglycerides

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DRUG APPROVAL; DRUG EFFICACY; DRUG EXCRETION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; JAPAN; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; ARTICLE; POSTMARKETING SURVEILLANCE;

HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; PRODUCT SURVEILLANCE, POSTMARKETING; PYRROLES; QUINOLINES; SIMVASTATIN;

EID: 77954655894     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0535     Document Type: Review

References (31)

1. Centers for Disease Control and Prevention. National Center for Health Statistics. Leading Causes of Death by Age Group, All Females - United States, 2004. Hyattsville, MD: Department of Health and Human Services Web site. http://www.cdc.gov/women/lcod/04all.pdf. Accessed February 2, 2010.
2. Centers for Disease Control and Prevention. Disparities in premature deaths from heart disease-50 States and the District of Columbia, 2001. MMWR Morb Mortal Wkly Rep. 2004;53: 121-125.
3. Watson KE. The past, present, and future of statin therapy. Rev Cardiovasc Med. 2005;6: 129-139. (Pubitemid 41479704)
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
5. Massy ZA. Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 1996;347:102-103. (Pubitemid 26017860)
6. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-1582.
7. Steinberg D. An interpretative history of the cholesterol controversy, part V: the discovery of statins and the end of the controversy. J Lipid Res. 2006;47:1339-1351. (Pubitemid 44079887)
8. Roche VF. Antihyperlipidemic statins: a self-contained, clinically relevant medicinal chemistry lesson. Am J Pharm Educ. 2005;69. http://www.ajpe.org/view.asp?art=aj690477&pdf=yes. Accessed February 3, 2010.
9. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160-1164. (Pubitemid 32440937)
10. US Department of Health and Human Services. US Food and Drug Administration Web site. FDA Approves New Cholesterol-Lowering Drug. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175046.htm. Accessed December 10, 2009.
11. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung. 1997;47:904-909. (Pubitemid 27357013)
12. Hayashi T, Yokote K, Saito Y, Iguchi SA. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother. 2007;8:2315-2327. (Pubitemid 350001592)
13. Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia: dose-finding study using the double-bind, three-group parallel comparison. Arzneimittelforschung. 2002;52:251-255. (Pubitemid 34438222)
14. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162:373-379. (Pubitemid 34457943)
15. Park S, Kang HJ, Rim SJ, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther. 2005;27:1074-1082. (Pubitemid 41262465)
16. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4:291-302.
17. Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:157-164. (Pubitemid 34615738)
18. Kawai T, Tokui M, Funae O, et al. Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care. 2005;28:2980-2981. (Pubitemid 43942938)
19. Miyauchi K, Kimura T, Morimoto T, et al. Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS): rationale and design. Circ J. 2006;70:1624-1628. (Pubitemid 44819881)
20. Hiro T, Kimura T, Morimoto T, et al. Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS). J Am Coll Cardiol. 2009;54:293-302.
21. Fujino H, Kojima J, Yamada Y, et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans. Xenobio Metab Dispos. 1999;14:79-91.
22. Kimata H, Fujino H, Koide T, et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats. Xenobio Metab Dispos. 1998;13:484-498.
23. Fujino H, Saito T, Tsunenari Y, et al. Interaction between several medicines and statins. Arzneimittelforschung. 2003;53:145-153. (Pubitemid 36363609)
24. Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet)-LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther. 2008; 36:709-731.
25. Lipitor® [package insert]. New York, NY: Pfizer; 2009.
26. Lescol® [package insert]. East Hanover, NJ: Novartis; 2006.
27. Mevacor® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2009.
28. Pravachol® [package insert]. New York, NY: Bristol-Myers Squibb; 2007.
29. Crestor® [package insert]. Wilmington, DE: AstraZeneca; 2010.
30. Zocor® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2010.
31. Livalo® [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc., 2009.